<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05616104</url>
  </required_header>
  <id_info>
    <org_study_id>VMG-2022-001</org_study_id>
    <nct_id>NCT05616104</nct_id>
  </id_info>
  <brief_title>FLEX FIRST Registry Research Protocol</brief_title>
  <official_title>FLEX FIRST Registry Research Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VentureMed Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VentureMed Group Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, observational study evaluating the clinical use and outcomes of the FLEX Vessel&#xD;
      Prep (VP) system in arteriovenous fistulae or grafts presenting with clinical or hemodynamic&#xD;
      abnormalities following 12 months post treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, observational study evaluating the clinical use and outcomes of the FLEX Vessel&#xD;
      Prep (VP) system in arteriovenous fistulae or grafts presenting with clinical or hemodynamic&#xD;
      abnormalities in real-world subjects per the Institution's standard practice and at 1-, 6-,&#xD;
      and 12-months following treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2022</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Target Lesion Primary Patency Rate</measure>
    <time_frame>6 months post procedure</time_frame>
    <description>Defined as freedom from clinically driven target lesion re-intervention (CD-TLR) or access circuit thrombosis measured through 6-months post- procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Event Rate</measure>
    <time_frame>1 month</time_frame>
    <description>Defined as the Serious Adverse Event (SAE) rate involving the AV access circuit through 1-month post-procedure.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Arteriovenous Fistula</condition>
  <condition>Arteriovenous Graft</condition>
  <condition>Fistula</condition>
  <condition>Arterial Occlusive Diseases</condition>
  <arm_group>
    <arm_group_label>FLEX Vessel Prep followed by angioplasty</arm_group_label>
    <description>Eligible subjects will be treated with the FLEX Vessel Prep system followed by balloon angioplasty.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FLEX Vessel Prep System</intervention_name>
    <description>The FLEX Vessel Prep System to create circumferential, continuous micro-incisions along the length of the stenosis by performing a retrograde pullback through the lesion.&#xD;
Following FLEX, standard balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding Instructions for Use. Once advanced into the lesion, the balloon should be inflated according to the site's standard of care.</description>
    <arm_group_label>FLEX Vessel Prep followed by angioplasty</arm_group_label>
    <other_name>Balloon Angioplasty</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with AVF/AVG stenosis who are eligible for FLEX/Angioplasty treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is ≥18 years of age.&#xD;
&#xD;
          2. Subject is currently scheduled to undergo an endovascular intervention of&#xD;
             arteriovenous fistula or graft due to clinical and hemodynamic abnormalities meeting&#xD;
             the KDOQI Guidelines for AV access dysfunction:&#xD;
&#xD;
               -  Elevated venous pressure during hemodialysis,&#xD;
&#xD;
               -  Abnormal physical findings, and&#xD;
&#xD;
               -  Unexplained decrease in delivered dialysis dose.&#xD;
&#xD;
          3. Subject has a reasonable expectation of remaining on hemodialysis for ≥12 months.&#xD;
&#xD;
          4. Subject is legally competent, informed of the study, voluntarily agrees to&#xD;
             participate, and signs the informed consent form.&#xD;
&#xD;
          5. Subject understands the study and is willing and able to comply with the follow-up&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a known or suspected systemic infection.&#xD;
&#xD;
          2. Subject has a known or suspected infection of the hemodialysis graft.&#xD;
&#xD;
          3. Subject has an untreatable allergy to radiographic contrast material.&#xD;
&#xD;
          4. In the opinion of the operating physician, the subject's hemodialysis access is&#xD;
             unsuitable for endovascular treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jill Schweiger</last_name>
    <phone>763-296-2021</phone>
    <email>jschweiger@venturemedgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Open Access Vascular Access</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Pazos</last_name>
    </contact>
    <investigator>
      <last_name>Sanford Altman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Vascular Surgery Center</name>
      <address>
        <city>New Brighton</city>
        <state>Minnesota</state>
        <zip>55112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Guest</last_name>
    </contact>
    <investigator>
      <last_name>Scott R Schultz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dialysis Access Institute</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Lawson</last_name>
    </contact>
    <contact_backup>
      <last_name>Virginia Anderson</last_name>
    </contact_backup>
    <investigator>
      <last_name>John Aruny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional Health</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darla Howard</last_name>
    </contact>
    <investigator>
      <last_name>Ari Kramer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>April 11, 2023</last_update_submitted>
  <last_update_submitted_qc>April 11, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

